Ilex Medical (ILX) Ratios
0 Followers
Ilex Medical Ratios
IL:ILX's free cash flow for Q2 2026 was ₪28.05M. For the 2026 fiscal year, IL:ILX's free cash flow was decreased by ₪-19.02M and operating cash flow was ₪47.07M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.83 | 2.68 | 2.46 | 2.81 | 2.63 |
| Quick Ratio | 2.07 | 2.09 | 1.89 | 2.17 | 2.15 |
| Cash Ratio | 0.69 | 0.66 | 0.53 | 0.89 | 1.08 |
| Solvency Ratio | 0.34 | 0.25 | 0.25 | 0.53 | 0.83 |
| Operating Cash Flow Ratio | 0.29 | 0.30 | 0.29 | 0.31 | 1.13 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 262.48 | 194.28 | 124.76 | 238.90 |
| Net Current Asset Value | ₪ 415.64M | ₪ 370.89M | ₪ 293.40M | ₪ 348.75M | ₪ 332.23M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.05 | 0.05 | 0.05 | 0.06 | 0.07 |
| Debt-to-Equity Ratio | 0.07 | 0.08 | 0.08 | 0.08 | 0.10 |
| Debt-to-Capital Ratio | 0.06 | 0.07 | 0.07 | 0.08 | 0.09 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.45 | 1.54 | 1.63 | 1.47 | 1.52 |
| Debt Service Coverage Ratio | 48.86 | 35.57 | 34.25 | 70.99 | 79.49 |
| Interest Coverage Ratio | 25.49 | 27.55 | 30.89 | 98.39 | 124.23 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 4.35 | 4.81 | 4.55 | 4.71 | 5.39 |
| Net Debt to EBITDA | -1.03 | -1.11 | -0.81 | -0.79 | -0.65 |
| Profitability Margins | |||||
| Gross Profit Margin | 22.76% | 23.50% | 24.91% | 32.67% | 35.76% |
| EBIT Margin | 8.20% | 6.96% | 8.15% | 15.86% | 24.26% |
| EBITDA Margin | 13.52% | 12.29% | 13.28% | 21.59% | 29.02% |
| Operating Profit Margin | 6.01% | 7.25% | 8.81% | 18.12% | 23.56% |
| Pretax Profit Margin | 7.96% | 6.69% | 7.46% | 15.67% | 24.07% |
| Net Profit Margin | 5.97% | 4.24% | 5.47% | 11.70% | 18.61% |
| Continuous Operations Profit Margin | 5.97% | 4.97% | 5.47% | 11.70% | 18.61% |
| Net Income Per EBT | 74.94% | 63.28% | 73.32% | 74.68% | 77.34% |
| EBT Per EBIT | 132.51% | 92.33% | 84.61% | 86.48% | 102.16% |
| Return on Assets (ROA) | 5.60% | 3.92% | 5.01% | 11.36% | 22.57% |
| Return on Equity (ROE) | 8.11% | 6.03% | 8.16% | 16.66% | 34.31% |
| Return on Capital Employed (ROCE) | 7.59% | 9.19% | 11.12% | 23.48% | 39.37% |
| Return on Invested Capital (ROIC) | 5.58% | 6.70% | 8.03% | 17.21% | 29.83% |
| Return on Tangible Assets | 5.71% | 4.02% | 5.15% | 11.78% | 23.26% |
| Earnings Yield | 7.43% | 4.67% | 7.73% | 9.24% | 10.77% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.50 | 3.68 | 3.24 | 3.51 | 4.82 |
| Payables Turnover | 5.11 | 5.85 | 4.06 | 4.13 | 5.48 |
| Inventory Turnover | 3.70 | 4.46 | 4.38 | 4.03 | 5.86 |
| Fixed Asset Turnover | 6.32 | 5.92 | 5.79 | 6.01 | 7.01 |
| Asset Turnover | 0.94 | 0.93 | 0.92 | 0.97 | 1.21 |
| Working Capital Turnover Ratio | 2.03 | 2.15 | 2.28 | 2.18 | 3.16 |
| Cash Conversion Cycle | 131.52 | 118.64 | 106.32 | 106.02 | 71.36 |
| Days of Sales Outstanding | 104.40 | 99.23 | 112.81 | 103.85 | 75.68 |
| Days of Inventory Outstanding | 98.60 | 81.85 | 83.38 | 90.59 | 62.29 |
| Days of Payables Outstanding | 71.48 | 62.44 | 89.87 | 88.43 | 66.61 |
| Operating Cycle | 203.00 | 181.08 | 196.19 | 194.45 | 137.97 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 6.50 | 7.31 | 7.19 | 6.18 | 23.99 |
| Free Cash Flow Per Share | 3.82 | 4.32 | 2.53 | 3.67 | 20.21 |
| Dividend Paid and CapEx Coverage Ratio | 1.67 | 1.68 | 1.09 | 0.79 | 2.64 |
| Capital Expenditure Coverage Ratio | 2.42 | 2.45 | 1.54 | 2.46 | 6.35 |
| Operating Cash Flow Coverage Ratio | 1.56 | 1.59 | 1.67 | 1.35 | 4.61 |
| Operating Cash Flow to Sales Ratio | 0.08 | 0.09 | 0.09 | 0.08 | 0.26 |
| Free Cash Flow Yield | 5.73% | 5.79% | 4.30% | 3.74% | 12.43% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 13.47 | 21.40 | 12.93 | 10.82 | 9.29 |
| Price-to-Sales (P/S) Ratio | 0.80 | 0.91 | 0.71 | 1.27 | 1.73 |
| Price-to-Book (P/B) Ratio | 1.09 | 1.29 | 1.06 | 1.80 | 3.19 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 17.46 | 17.27 | 23.28 | 26.71 | 8.04 |
| Price-to-Operating Cash Flow Ratio | 10.26 | 10.22 | 8.18 | 15.85 | 6.78 |
| Price-to-Earnings Growth (PEG) Ratio | 0.32 | -0.92 | -0.26 | -0.22 | 0.17 |
| Enterprise Value Multiple | 4.91 | 6.26 | 4.51 | 5.07 | 5.31 |
| Enterprise Value | 618.41M | 708.32M | 557.85M | 955.94M | 1.63B |
| EV to EBITDA | 4.91 | 6.26 | 4.51 | 5.07 | 5.31 |
| EV to Sales | 0.66 | 0.77 | 0.60 | 1.10 | 1.54 |
| EV to Free Cash Flow | 14.45 | 14.67 | 19.74 | 23.10 | 7.16 |
| EV to Operating Cash Flow | 8.49 | 8.68 | 6.94 | 13.71 | 6.04 |
| Tangible Book Value Per Share | 59.38 | 55.72 | 53.20 | 51.51 | 48.72 |
| Shareholders’ Equity Per Share | 61.07 | 57.87 | 55.72 | 54.36 | 51.02 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.25 | 0.26 | 0.27 | 0.25 | 0.23 |
| Revenue Per Share | 83.02 | 82.39 | 83.19 | 77.36 | 94.05 |
| Net Income Per Share | 4.95 | 3.49 | 4.55 | 9.05 | 17.51 |
| Tax Burden | 0.75 | 0.63 | 0.73 | 0.75 | 0.77 |
| Interest Burden | 0.97 | 0.96 | 0.91 | 0.99 | 0.99 |
| Research & Development to Revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| SG&A to Revenue | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.98 | 1.49 | 1.16 | 0.51 | 1.06 |
Currency in ILS
